Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Cash from Investing Activities (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Cash from Investing Activities for 2 consecutive years, with $11.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities rose 143487.5% to $11.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $69.3 million, a N/A change, with the full-year FY2024 number at $8.2 million, up 107.78% from a year prior.
  • Cash from Investing Activities was $11.5 million for Q3 2025 at Pyxis Oncology, down from $15.3 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $26.7 million in Q4 2024 to a low of -$18.5 million in Q1 2024.